Dov Pharmaceuticals fka DOVP

[Virgilio]

Payment default will come in if they ain't able to raise 50M in the next 8 business days. I say 50M because in my own estimates DOVP will finish the quarter with approx 37M in cash and they would need 17M in order to fund the 2 next quarters and to raise cash with other partnerships in order to do that.

Actually, though timing is ticking out, there are a whole lot of potential in order to raise those 50M now, and there's much more now than 1 week before, and I'll tell you why (weird the article posted didn't really examine all of the potentials out there).

1) Dov 21,947 is now in full control of DOVP, which can now seek broak partnerships for the compound;
2) Merck called the deal off also for DOV 216,303. IMO they did so just because the original agreement wasn't really worth it anymore without DOV 21,947, so perhaps I do not exclude that they called the deal off and that DOVP will now sell/partner back the drug to them in a different agreement. If we split the agreement into 2 and think that they would have get 150M for each drug in milestone payments and approvals for different countries, why couldn't DOVP just sell DOV 216,303 to them for...say...80M leaving only the royalties at stake?
3) True the real money for bicifadine is in chronic pain, but they tended to forget that bicifadine has a different composition than other drugs out there. The Meta-analisys somehow gave some good data for chronic pain, and that doesn't mean that some other PIII trials may be designed and give better results. Plus there's the acute pain program, and - I don't understand why the article didn't mention this - there's also bicifadine with ibuprofen, which showed great results in OA PII interim results. Weird enough I heard no mention of this combination for chronic pain pathologies...is OA acute pain? I don't think so.
4) Noone mentioned Dov Diltiazem nor Dov 102,677...Diltiazem is ready for PIII and is believed to have better potentials than current drugs out there.

This is about all, so what they need is prioritize some of these partnerships, out of:

1) Dov 21,947;
2) Dov 216,303;
3) Dov 102,677;
4) Dov Diltiazem;
5) Bicifadine for acute and chronic pain (alone);
6) Bicifadine for acute and chronic pain (with ibuprofen).

I am also curious to see the end of quarter results, as DOVP will have now to register those 22.5M of the deals it had with Merck as revenue all in a shot during current quarter.